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ABSTRACT
Previous studies on the pharmacokinetics of 3H-digoxin in the rat have been based on total
radioactivity in the plasma. even though the drug is extensively metabolized in this species.
A comparison of total radioactivity vs. unchanged drug in rat plasma after administration of
3H-digoxin clearly showed the need to separate digoxin from its metabolites. The pharma-
cokinetics of digoxin were therefore examined using solvent extraction and thin-layer chroma-
tography to isolate unchanged drug. Digoxin levels after a 1 mg/kg iv dose were measured in
the plasma and urine of adult male rats in which the bile duct or the ureters had been ligated.
as well as in sham-operated controls. In all cases. digoxin concentrations were best do-
scribed by a two-compartment open model. Digoxin was rapidly eliminated from the plasma
of controls. with a half-life of 2.5 hr. a volume of distribution of 3.6 liter/kg. and a renal
clearance somewhat lower than the glomerular filtration rate. No significant change in these
parameters was observed in rats with bile duct ligation. The total body clearance of 5.77
mI/mm in the controls was reduced by only 10% in the bile duct-ligated rats. In animals with
bilateral ureter ligation. the body clearance was reduced by 3tY36 and the plasma half-life of
digoxin was increased to 4 hr. although no significant change in the apparent volume of distri-
bution was noted. Approximately 60% of the total body clearance was unaffected by bile duct
and ureter ligations. and was assumed to be due to biotransformation. Biliary excretion was
found to be important for digoxigenin bisdigitoxoside. inasmuch as rats with bile duct ligation
showed elevated metabolite levels in the plasma as well as a 3-fold increase in renal excre-
tion of the bisglycoside.
In healthy man, digoxin is cleared by the
kidneys at a rate slightly greater than the glomeru-
lar filtration rate ( I ). Since urinary excretion of the
unchanged glycoside is the main mode of elimina-
tion of digoxin in patients with normal renal
function, a decreased body clearance, an increased
half-life, and decreased dosage requirements are
observed in patients with renal insufficiency (2 -4).
More recently, several workers have suggested that
the volume of distribution of digoxin is decreased
in patients with renal failure (5, 6).
The current interest in the absorption, distribu-
tion, and elimination of digoxin, as well as in the
influence of disease on these processes, is a reflec-
tion of the clinical problems encountered in the use
of this cardiac glycoside and indicates a need to
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determine an appropriate animal model which
would perniit a more intensive examination of the
pharmacokinetics of this drug from a physiological
and pathophysiological point of view. Digoxin is
metabolized in a similar fashion in man (2, 7, 8)
and in the rat (9, 10), although the rates of
metabolism differ greatly. A stepwise cleavage of
the sugar residues with subsequent conjugation of
the monodigotoxoside and aglycone has been
indicated (I I, 12). In man, the metabolic break-
down of digoxin accounts for only a small fraction
of an iv dose, as over 73% of the dose is excreted
unchanged in the urine (13). The rat, on the other
hand, ultimately metabolizes more than 70% of an
ip dose ( 14). Pretreatment with certain microsomal
enzyme inducers can increase the degree of me-
tabolism to as much as 98% of the dose (14, 15).
Protein binding is relatively low in both species
and accounts for about 25% of digoxin in the
plasma ( I 6). Previous studies in the rat have relied
solely on the measurement of total radioactivity
(17- 19). Since digoxin is extensively metabolized
DIGOXIN PHARMACOKINETICS IN THE RAT 89
in this species and metabolites can be detected in
rat blood within 3 mm after injection (20), one
must regard previous pharmacokinetic estimates
based on total radioactivity as erroneous.
In the present study we have reexamined the
pharmacokinetics of digoxin in the rat by use of
solvent extraction and thin-layer chromatography
to separate digoxin from its metabolites. Further
insight as to the role of biliary and urinary
excretion on the disposition of digoxin has been
gained by also determining the pharmacokinetics
of the drug in rats in which the bile duct or
ureters had been ligated.
Methods
Drugs. The chromatography standards digoxin and
digoxigenin bisdigitoxoside were purchased from Aldrich
Chemical Co. (Milwaukee, Wise.) and Boehringer
Mannheim Co. (New York, N.Y.), respectively. Triti-
ated digoxin, labeled at the l2a-position (6.19 Ci/mmol)
was obtained from New England Nuclear Corp. (Boston,
Mass.).
Animals and Treatments. Male Sprague-Dawley rats
(300-420 g) were anesthetized with ether, thejugular vein
was cannulated with Silastic tubing (Dow Corning,
Midland, Mich.), and the bile duct or the ureters were
exposed by a midline abdominal incision and ligated. The
bile duct and ureters were also isolated and traumatized
in control rats, but no ligations were performed. The
animals were allowed to recover overnight with food and
water available. Periodic blood samples were taken from
some ureter-ligated and control rats during recovery, for
plasma creatinine determinations.
A I-mg/kg dose, consisting of320ig ofdigoxin and I
Mg (20 aCi) of 3H-digoxin in 0.32 ml of 40% ethanol, was
administered as a bolus through the jugular vein can-
nula. Blood samples were withdrawn from the cannula
at various times after dosing for 12 hr and collected in
heparinized tubes. For the first 4 hr. nine 0.1-mI blood
samples were taken. Sampling was much less frequent
thereafter, but blood volumes ofO.2 0.3 mI/sample were
required. No significant effects on hematocrit, which
averaged 0.42, were observed.
The animals were housed in individual metabolic cages
and allowed food and water ad lib throughout the
experiment. Urine was collected at 4-hr intervals for 12
hr. At the end ofeach interval, voiding ofthe bladder was
induced with ether. The cages were then washed with
water and the rinse was added to the urine.
Analytical Procedures. Plasma samples were ex-
tracted 3 times with a 3- to 5-fold excess of chloroform/
methanol (1:1, v/v). The pooled extracts were then
streaked on silica gel plates and chromatographed. The
extraction method recovered > 98% ofthe radioactivity
from rat plasma to which 3H-digoxin had been added.
The diluted urine was filtered and extracted 3 times
with a 3-fold excess ofchloroform. In all cases more than
80% of the radioactivity of the urine sample was
recovered in the organic phase. The volume of the
organic phase was then reduced under vacuum at room
temperature. Chromatography of the aqueous and or-
ganic phases showed that over 90% of the digoxin was
extracted into the organic layer.
Good separation of digoxin and digoxigenin bis-
digitoxoside from other metabolites in plasma and urine
was achieved by thin-layer chromatography with a
solvent.system described by Carvalhas and Figueira (21).
The RF of digoxin was 0.28, and that of the bisglyco-
side was 0.41. Aluminum sheets precoated with silica
gel 60F-254 (EM. Laboratories, Elmsford, N.Y.) of
0.25-mm thickness, were developed twice in ethyl ace-
tate/chloroform/acetic acid (90:5:5, v/v). Both the
digoxin and bisglycoside spots were visualized by spray-
ing the plate with 3,5-dinitrobenzoic acid and NaOH in
methanol to develop a violet color. By comparison,
‘H-digoxin was found to be greater than 96% pure. The
spots attributable to digoxin from chromatograms of
biological samples were scraped into scintillation vials
and counted in a dioxane-based scintillant (22) for a
sufficient time to yield a standard error of less than 10%.
Corrections for quenching were made with an external
standard. Levels of the bisglycoside were similarly mea-
sured in the urine and in the 2-, 6-, 10-, and 12-hr blood
sam pIes.
Plasma creatinine was measured colorimetrically at
5 10 nm according to Heinegrd and Tiderstr#{246}m (23). The
assay solution consisted of I ml of reagent solution and
100 M1 of plasma. Absorbance was a linear function of
concentration up to 7.5 mg/l00 ml creatinine.
Data Analysis. Data for digoxin concentration in the
plasma vs. time for individual rats were described by a
biexponential expression, viz. C = A exp ( -at) + B exp
( -at), where C is plasma concentration, t is time, and A,
B, a and fi are constants, with use of a nonlinear
least-squares regression program (24). The correlation
coefficient was 0.993 or better in all cases. No improve-
ment in goodness-of-fit was noted by adding an addi-
tional exponential term as has been suggested for describ-
ing the time course ofdigoxin plasma levels in man (25).
Therefore, the pharmacokinetics of digoxin in the rat
may be described by a two-compartment open model,
with elimination occurring in the central compartment
(26). The total area under the curve of plasma drug
concentration vs. time was calculated from the sum of
A /a and B/fl, the volume of the central compartment is
given by the iv dose divided by (A +B), the total body
clearance is equal to dose divided by area, the half-life is
simply 0.693/a, and the apparent volume of distribution
is calculated by dividing the total body clearance by .
The renal clearance of digoxin was calculated for three
4-hr intervals by dividing the amount excreted during the
interval by the area under the curve of plasma level vs.
time over that interval. The renal clearance of the
bisglycoside was calculated for each interval by dividing
the average excretion rate of the metabolite by its
concentration in the plasma at the midpoint of the
interval.
Time (hr)
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Differences between parameters calculated for differ-
ent treatments were evaluated as to statistical signifi-
cance by means of Student’s t-test.
Results
The plasma levels of digoxin in adult male rats
as a function of time after iv administration of
about I mg of 3H-digoxin per kg are shown in fig.
I. Immediately after injection, digoxin levels in the
plasma of control animals decline rapidly so that
within an hour drug levels are less than half of the
initial level. Similar results have been obtained in
the rat ( I 7) and in man ( I 3), when total radioactiv-
ity was measured. The initial rapid decline presum-
ably largely reflects distribution of the drug from
the intravascular compartment. Under all experi-
mental conditions, digoxin was lost from the
plasma in a biphasic fashion and the data were well
described by a biexponential expression, the coeffi-
cients of which are listed in table I . Assuming that
digoxin kinetics can be described by a two-com-
partment open model in the rat, certain phar-
macokinetic parameters were calculated and these
are also summarized in table I.
Digoxin is rapidly eliminated from the plasma of
sham-operated control rats. The half-life of the
drug was about 2.5 hr. This estimate is substan-
tially less than the values of 4.5 (17), 9 (18), and
13.5 hr ( 19), all of which were derived from total
radioactivity data in the rat.
As seen in fig. I and table I, ligation of the
common bile duct has little if any influence on the
pharmacokinetics of digoxin in the rat. The half-
life under these conditions is virtually identical to
that observed in control rats while the total body
clearance is reduced only about 10% on the
average.
Ligation of the ureters presented clear indica-
tions of renal failure. In a series of 5 control
animals, plasma creatinine levels remained within
the range of 0.6 to 1.2 mg/lOO ml for 2 days
after sham surgery. In 6 animals with bilateral
ureter ligation, plasma creatinine levels rose to
4 mg/l00 ml after the first day and to 5.5 to
6.5 mg/l00 ml after 2 days. These creatinine
levels are in good agreement with those measured
after bilateral nephrectomy (27).
The pharmacokinetics of digoxin in rats that
had undergone bilateral ureter ligation were
clearly different from the results in control ani-
mals. The half-life of the drug was significantly (p
< 0.05) increased from 2.5 to 4 hr while the total
body clearance was reduced about 30% (0.05 <
P < 0.10).
As in man, the volume of the central compart-
ment (Va) as well as the apparent volume of
distribution (V) of digoxin in the rat was large
relative to body weight, averaging 400 ml and I 200
ml, respectively, in control animals. Bile duct or
ureter ligation had no significant effect on these
parameters. The relatively large apparent volume
of distribution indicates that within minutes after
injection and thereafter, a very small percentage of
the total body load of digoxin is in the intravascu-
lar space.
FIG. I . Semiogarithmic plots ofdigoxin concentration in
the plasma vs. time after iv administration of I mg of
3H-digoxin per kg to control (#{149}),bile duct-ligated (0)
and ureter-ligated () rats.
Each curve represents a single rat.
TABLE I
Pharmacokinetic parameters estimazedfrom the curve of
plasma digoxin concentration vs. time after iv injection
of I mg of digoxin-3H per kg to rats under different
experimental conditions
Data are expressed as means ± SD.








A (sg/ml) 0.75 ± 0.40 0.65 ± 0.26 0.48 ± 0.14
B (ag/mI) 0.21 ± 0.08 0.27 ± 0.1 I 0.20 ± 0.07
a(hr’) 2.72 ± 1.02 2.59 ± 0.74 1.82 ± 0.27
$(hr’) 0.28 ± 0.03 0.28 ± 0.03 0.18 ± 0.03c
Half-life, tN 2.46 ± 0.26 2.48 ± 0.27 3.96 ± 0.68
(hr)
Bodyclearance 5.77 ± 1.88 5.18 ± 1.75 4.12 ± 1.45
(mI/mm)
V#{176}(ml) 390 ± 162 400 ± 195 489 ± IIS
Vb(mI) 1219 ± 358 1114 ± 399 1376 ± 325
a Volume of the central compartment.
b Apparent volume of distribution.
 Significantly different (p < 0.05) from control mean.
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Direct estimates of the renal clearance of di-
goxin and its metabolite, digoxigenin bisdigitoxo-
side, in control and bile duct-ligated rats are
presented in table 2. Digoxin is cleared by the rat
kidneys at a constant rate of about I mI/mm.
Similar values were observed in rats that had
undergone bile duct ligation. This corresponds to a
value ofabout 3 mI/mm/kg which is about half the
glomerular filtration rate in the rat (28). Renal
clearance of the bisglycoside was quite similar to
that of digoxin in control animals. In rats with
ligated bile ducts, the elevated plasma levels of the
metabolite (table 3) were attended by significant
increases (p < 0.05) in the renal clearance of the
bisglycoside compared to that observed in control
animals.
The cumulative urinary excretion ofdigoxin was
variable. In control rats 17.4 ± 4.7% (SD, N - 5)
of the dose was excreted in the first I 2 hr. Over the
same interval, 23.9 ± 8.9% (SD, N = 6) of the
dose was recovered from the urine of bile duct-
ligated rats as unmetabolized digoxin. Bile duct
ligation had a very pronounced effect on the
TABLE 2
Renal clearance of digoxin and its bisglycoside






Bile Duct Bile DuctControl Control
(N 4) Ligation (N = 4) Ligation
= (N=3) (N=3)
hr mi/mm
0-4 0.94 ± 0.36 1.33 ± 0.11 1.01 ± 0.30 1.95 ± O.22
4-8 1.1 1 ± 0.33 1.15 ± 0.17 1.24 ± 0.53 2.07 ± 0.I2
8-12 1.07 ± 0.43 1.24 ± 0.32 “ 2.59 ± 0.68
a Expressed as mean ± SD.
a Values ranged from 0.45 to 3.27 mI/mm.
 Significantly different (p < 0.05) from control mean.
TABLE 3
Plasma concentrations of digoxigenin bisdigitoxoside
after iv administration of 3H-digoxin to rats under
different experimental conditions












2 32±9 63±24 39±4
6 11±3 22±8 19±2
10 5.7 ± 2.1 8.6 ± 1.7 13 ± 3
12 4.7±.9 7.3±2.2 11±2
fraction of the dose excreted as the bisglycoside,
which increased almost three-fold during the 12-hr
collection interval (from 5% in control rats to 13%
in bile duct-ligated rats).
Discussion
The present study reveals substantial qualitative
and quantitative differences n the pharmacokinet-
ics ofdigoxin in the rat and man. In contrast to the
situation in man where metabolism ofdigoxin is a
minor elimination pathway, we have confirmed
previous observations (14) as to the major role of
biotransformation in the elimination of digoxin in
the rat. Based on total body clearance values of
5.77, 5.18, and 4.12 mI/mm in control, bile
duct-ligated, and ureter-ligated rats, respectively,
one can infer that net biliary secretion accounts for
about 10% of the elimination of digoxin, while
urinary excretion accounts for an additional 30%.
Assuming that the physiological changes resulting
from the ligations did not affect metabolic clear-
ance, biotransformation would account for the
remaining 60% ofthe elimination ofdigoxin in the
rat. A lower estimate of the contribution of renal
excretion to digoxin elimination is arrived at when
one considers that only about 17% of the dose is
excreted in the urine of control rats as unchanged
digoxin within 12 hr after injection. The quantita-
tive estimate of the minor contribution of net
biliary excretion is supported by the fact that only
an additional 7% of the dose is excreted as intact
digoxin in the urine of bile duct-ligated rats as
compared to the cumulative excretion in control
animals.
It is evident that digoxin is very rapidly elimi-
nated in the rat, contrary to previous reports based
on total radioactivity ( 18, 19) and in contrast to the
relatively slow elimination ofthe drug in man. The
2.5-hr half-life of digoxin in the rat is less than
one-tenth that observed in man (13). By the same
token, the total body clearance of digoxin in the
rat (17 mI/mm/kg) is about 7 times that found in
patients with normal renal function (29).
Several previous studies have demonstrated that
digoxin per se is secreted in rat bile ( I 4, 15, I 9, 30).
Based on the pharmacokinetic profile generated in
the present study and data reported by Cox and
Wright (31) in rats with biliary fistulas, one would
estimate that about 15 20% of an iv dose of
digoxin is secreted in the rat bile. However, one
must conclude that an efficient enterohepatic cir-
culation of digoxin exists in the rat (19), for we
observed little evidence of fecal excretion. Al-
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clearance and a small increase in urinary output of
digoxin in bile duct-ligated rats, as compared to
that observed in control animals, neither change
was statistically significant.
Net biliars excretion appears to play a much
more important role in the elimination of digox-
igenin bisdigitoxoside. Considerably higher levels
of the bisglycoside were observed in the plasma of
rats that had undergone bile duct ligation and a
several-fold increase in the urinary recovery of the
metabolite was noted as well. These observations
are supported by Wirth and Fr#{246}lich (14) who
found about 35% of an iv dose of digoxin in the
feces in the form of the bisglycoside.
Experimentally induced renal failure in the rat
produced changes in the pharmacokinetics of
digoxin that were qualitatively similar to the
effects of renal impairment in man. As in man,
renal failure in the rat increased the half-life and
decreased the total body clearance of digoxin,
albeit to a more limited extent. Certain similarities
were also found with respect to distribution vol-
umes ofdigoxin in man and rat. The volume of the
central compartment in the rat (approximately 400
ml) is about twice the volume of body water. The
volume of the central compartment for digoxin in
man is also approximately twice that ofbody water
(5). The total apparent volume of distribution of
digoxin expressed in terms of mI/kg, however, is
twice as large in man (29) as in the rat. The reasons
for this difference are not apparent.
In man, digoxin is cleared by the kidneys at a
rate approximating the glomerular filtration rate,
although evidence exists for both tubular secretion
and reabsorption (32). The renal clearances of both
digoxin and digoxigenin bisdigitoxoside in the rat
were found to be lower than the glomerular
filtration rate, suggesting net tubular reabsorption.
In the case of the bisglycoside the reabsorption
process may be capacity-limited, for elevation of
the metabolite levels in the plasma, resulting from
bile duct ligation, produced a significant increase
in renal clearance compared to that observed in
control rats.
From an analytical standpoint, one of the most
important differences between rat and man, with
respect to digoxin,is in the utility oftotal radioac-
tivity data. Analysis of levels of total radioac-
tivity in the plasma after administration of 3H-
digoxin to human subjects provides a reasonable
estimate of the pharmacokinetics of the drug
(13). On the other hand, a very erroneous picture
of digoxin pharmacokinetics is seen if only total
radioactivity in the plasma is determined in the
rat. Fig. 2, which shows the time course of total
Time (hr)
FIG. 2. Semilogarizhmic plots oftotal radioactivity in the
plasma vs. time after iv administration of I mg of
3H-digoxin per kg to control (0) and bile duct-ligated
(A) rats.
A plot of digoxin concentration in the plasma vs.
time in a bile duct-ligated rat (0) is included for com-
parison. Each curve represents a single rat.
radioactivity in the plasma of a control and a
bile duct-ligated rat, as well as the time course
of digoxin in the plasma of a bile-duct ligated
rat (which is virtually identical to that observed
in control rats), after iv administration of equal
doses of 3H-digoxin, clearly reveals the degree
of error that is introduced by reliance on total
radioactivity data. The half-life of total tritium
activity in the control was estimated to be 83
hr and radioactivity was still measurable in the
plasma 2 weeks after dosing. Although bile duct
ligation had little effect on the pharmacokinetics of
digoxin, the bile duct ligated rat showed a radioac-
tivity half-life of43 hr. about one-halfofthat seen
in the control. Similar discrepancies were observed
with respect to estimates of distribution volumes,
total body clearance, and renal clearance. For
example, the renal clearance showed a continuous
decline with time for more than 24 hr after dosing.
These findings are not surprising, for the composi-
tion of total radioactivity in the rat plasma and
urine is continually changing after drug adminis-
tration. The inappropriateness of utilizing total
radioactivity’ data to characterize the pharmacoki-
netics of digoxin in the rat is evident.
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